Page last updated: 2024-10-26

doxepin and Chronic Insomnia

doxepin has been researched along with Chronic Insomnia in 36 studies

Doxepin: A dibenzoxepin tricyclic compound. It displays a range of pharmacological actions including maintaining adrenergic innervation. Its mechanism of action is not fully understood, but it appears to block reuptake of monoaminergic neurotransmitters into presynaptic terminals. It also possesses anticholinergic activity and modulates antagonism of histamine H(1)- and H(2)-receptors.
doxepin : A dibenzooxepine that is 6,11-dihydrodibenzo[b,e]oxepine substituted by a 3-(dimethylamino)propylidene group at position 11. It is used as an antidepressant drug.

Research Excerpts

ExcerptRelevanceReference
" He was prescribed doxepin for insomnia and four antiepileptics for seizures."8.31Chronic Doxepin Toxicity Masquerading as Epilepsy in a 10-Year-Old Boy. ( Burns, MM; Watson, CJ; Whitledge, JD, 2023)
" He was prescribed doxepin for insomnia and four antiepileptics for seizures."4.31Chronic Doxepin Toxicity Masquerading as Epilepsy in a 10-Year-Old Boy. ( Burns, MM; Watson, CJ; Whitledge, JD, 2023)
"Insomnia is a distinct disorder that is common, yet underrecognized and undertreated in primary care."3.01Insomnia Management: A Review and Update. ( Shaha, DP, 2023)
"Sleep outcomes included insomnia scales, clinical global impression, sleep diaries and actigraphy."2.78Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease -- a randomized study. ( Bailes, S; Creti, L; Fichten, C; Libman, E; Pelletier, A; Postuma, RB; Rios Romenets, S, 2013)
"In elderly adults with insomnia, DXP 6 mg produced significant improvements in sleep maintenance, sleep duration, and sleep quality endpoints that were sustained throughout the trial."2.77Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia. ( Essink, B; Heith Durrence, H; Lankford, A; Ludington, E; Rogowski, R; Roth, T, 2012)
"Patients meeting DSM-IV-TR criteria for primary insomnia were randomized to 35 days of nightly treatment with DXP 3 mg (n=75), DXP 6 mg (n=73), or placebo (PBO; n=73), followed by 2 nights of single-blind PBO to evaluate discontinuation (DC) effects."2.76Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. ( Durrence, HH; Jochelson, P; Krystal, AD; Lankford, A; Ludington, E; Rogowski, R; Roth, T, 2011)
"In this model of transient insomnia, DXP 6mg demonstrated significant improvements in sleep onset, sleep maintenance, sleep duration and sleep quality, and also appeared to reduce early morning awakenings."2.75Efficacy and safety of doxepin 6 mg in a model of transient insomnia. ( Heith Durrence, H; Jochelson, P; Lankford, A; Ludington, E; Peterson, G; Rogowski, R; Roth, T; Scharf, M, 2010)
"Subjects meeting DSM-IV-TR criteria for primary insomnia were randomized to 12 weeks of nightly treatment with doxepin (DXP) 1 mg (n = 77) or 3 mg (n = 82), or placebo (PBO; n = 81)."2.75Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia. ( Durrence, HH; Jochelson, P; Krystal, AD; Ludington, E; Rogowski, R; Roth, T; Scharf, M, 2010)
" All 3 doxepin doses had side effect profiles comparable to placebo, with no spontaneously reported anticholinergic effects, no memory impairment, and no significant next-day residual effects."2.73Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. ( Cohn, M; Ereshefsky, L; Feldman, N; Hull, S; Lankford, A; Mayleben, D; Rogowski, R; Roth, T; Scharf, M, 2008)
"In adults with primary insomnia, doxepin 1 mg, 3 mg, and 6 mg was well-tolerated and produced improvement in objective and subjective sleep maintenance and duration endpoints that persisted into the final hour of the night."2.73Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. ( Corser, B; Hull, S; Koshorek, G; Lankford, A; Rogowski, R; Roth, T; Schwartz, H; Seiden, D, 2007)
"Although in some patients rebound insomnia and specific side effects must be considered, our findings give a further rationale for the use of antidepressants in the treatment of primary insomnia."2.71The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. A placebo-controlled, double-blind, randomized, cross-over study followed by an open treatment over 3 weeks. ( Cohrs, S; Hajak, G; Huether, G; Jordan, W; Rodenbeck, A; Rüther, E, 2003)
"Long-term doxepin treatment of chronic insomniac patients not only improves sleep but also restores nocturnal melatonin secretion in these patients."2.68Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia. ( Adler, L; Bandelow, B; Hajak, G; Herrendorf, G; Huether, G; Rodenbeck, A; Rüther, E; Staedt, J, 1996)
"Understanding the risks and benefits of insomnia medications is critical."2.55Insomnia: Pharmacologic Therapy. ( Hainer, BL; Matheson, E, 2017)
"Geriatric patients often experience insomnia because of physiological and neurological changes that occur during the aging process."2.55A Review of Suvorexant, Doxepin, Ramelteon, and Tasimelteon for the Treatment of Insomnia in Geriatric Patients. ( Edmonds, C; Swanoski, M, 2017)
"Such approach to treatment of insomnia in depressed patients protects them against dependence on hypnotic drugs."2.47[The effects of antidepressants on sleep in depressed patients with particular reference to trazodone in comparison to agomelatine, amitriptyline, doxepin, mianserine and mirtazapine]. ( Wichniak, A; Wierzbicka, A, 2011)
"Doxepin is a tricyclic compound that has been used extensively for the treatment of depressive and anxiety disorders for approximately thirty years."2.45Low-dose doxepin for the treatment of insomnia: emerging data. ( Goforth, HW, 2009)
" Although these clinical actions are classically attributed to blockade of the H1 receptor, recent findings with H1 selective agents and H1 selective dosing of older agents are challenging these notions and suggest that some of the clinical limitations of current H1-blocking agents at their currently utilized doses could be attributable to other properties of these drugs, especially to their simultaneous actions on muscarinic, cholinergic, and adrenergic receptors."2.44Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. ( Stahl, SM, 2008)
"Pediatric insomnia is a widespread problem and especially difficult to manage in children with neurodevelopmental disorders."1.56Doxepin in children and adolescents with symptoms of insomnia: a single-center experience. ( Kothare, SV; Pavkovic, I; Shah, YD; Stringel, V, 2020)
" One of these compounds, 10a, showed equivalent efficacy in a rat EEG/EMG model to a previously identified clinical candidate and a potentially superior pharmacokinetic profile as determined from a human microdose study."1.36Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia. ( Beaton, G; Bradbury, MJ; Coon, T; Crowe, PD; Hernandez, LM; Hoare, SR; Huang, C; Jalali, K; Li, BF; Madan, A; Malany, S; Marinkovic, D; Moree, WJ; Petroski, RE; Sacaan, A; Tucci, FC; Wang, H; Wen, J; Yang, C; Yu, J; Zamani-Kord, S, 2010)
"Doxepin is a tricyclic antidepressant with a subnanomolar affinity for the histamine H(1) (H(1)) receptor."1.35Selective histamine H(1) antagonism: a novel approach to insomnia using low-dose doxepin. ( Owen, RT, 2009)
"Since insomnia was not influenced by clonidine, we offered 100 mg doxepine and/or 10 mg nitrazepam (the latter only until day 4 of treatment)."1.27[Clonidine for the treatment of heroin withdrawal syndrome]. ( Hermann, P; Presslich, O; Schanda, H, 1983)
"Desipramine was associated with a much higher frequency of jitteriness than was imipramine."1.27The jitteriness syndrome in panic disorder patients treated with antidepressants. ( Balon, R; Lycaki, H; Pohl, R; Yeragani, VK, 1988)

Research

Studies (36)

TimeframeStudies, this research(%)All Research%
pre-19905 (13.89)18.7374
1990's3 (8.33)18.2507
2000's8 (22.22)29.6817
2010's15 (41.67)24.3611
2020's5 (13.89)2.80

Authors

AuthorsStudies
Moree, WJ1
Li, BF1
Zamani-Kord, S1
Yu, J1
Coon, T1
Huang, C1
Marinkovic, D1
Tucci, FC1
Malany, S1
Bradbury, MJ1
Hernandez, LM1
Wen, J1
Wang, H1
Hoare, SR1
Petroski, RE1
Jalali, K1
Yang, C1
Sacaan, A1
Madan, A1
Crowe, PD1
Beaton, G1
De Crescenzo, F1
D'Alò, GL1
Ostinelli, EG1
Ciabattini, M1
Di Franco, V1
Watanabe, N1
Kurtulmus, A1
Tomlinson, A1
Mitrova, Z1
Foti, F1
Del Giovane, C1
Quested, DJ1
Cowen, PJ1
Barbui, C1
Amato, L1
Efthimiou, O1
Cipriani, A1
Shaha, DP1
Whitledge, JD1
Watson, CJ1
Burns, MM1
Shah, YD1
Stringel, V1
Pavkovic, I1
Kothare, SV1
Matheson, E1
Hainer, BL1
Um, MY1
Kim, S1
Jin, YH1
Yoon, M1
Yang, H1
Lee, J1
Jung, J1
Urade, Y1
Huang, ZL1
Kwon, S1
Cho, S1
Dupuis, G1
Vaugeois, JM1
Rios Romenets, S1
Creti, L1
Fichten, C1
Bailes, S1
Libman, E1
Pelletier, A1
Postuma, RB1
Crow, JM1
Yeung, WF1
Chung, KF1
Yung, KP1
Ng, TH1
Edmonds, C1
Swanoski, M1
Stahl, SM1
Scharf, M3
Rogowski, R6
Hull, S2
Cohn, M1
Mayleben, D1
Feldman, N1
Ereshefsky, L1
Lankford, A5
Roth, T6
Goforth, HW1
Owen, RT1
Weber, J1
Siddiqui, MA1
Wagstaff, AJ1
McCormack, PL1
Heith Durrence, H2
Jochelson, P3
Peterson, G1
Ludington, E4
Krystal, AD2
Durrence, HH2
Wichniak, A1
Wierzbicka, A1
Clark, MS1
Smith, PO1
Jamieson, B1
Essink, B1
Rodenbeck, A5
Cohrs, S2
Jordan, W1
Huether, G4
Rüther, E4
Hajak, G5
Singh, H1
Becker, PM1
Schwartz, H1
Koshorek, G1
Corser, B1
Seiden, D1
Schanda, H1
Presslich, O1
Hermann, P1
Adler, L1
Bandelow, B1
Herrendorf, G1
Staedt, J1
Voderholzer, U1
Riemann, D1
Hohagen, F1
Berger, M1
Elwan, O1
Taher, Y1
Allam, M1
Hassan, MA1
Smith, JA1
Renshaw, DC1
Pohl, R1
Yeragani, VK1
Balon, R1
Lycaki, H1
Lee, HK1

Reviews

12 reviews available for doxepin and Chronic Insomnia

ArticleYear
Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.
    Lancet (London, England), 2022, 07-16, Volume: 400, Issue:10347

    Topics: Adult; Benzodiazepines; Doxepin; Eszopiclone; Humans; Melatonin; Network Meta-Analysis; Randomized C

2022
Insomnia Management: A Review and Update.
    The Journal of family practice, 2023, Volume: 72, Issue:6 Suppl

    Topics: Doxepin; Humans; Sleep; Sleep Initiation and Maintenance Disorders; Zolpidem

2023
Insomnia: Pharmacologic Therapy.
    American family physician, 2017, Jul-01, Volume: 96, Issue:1

    Topics: Benzodiazepines; Doxepin; Humans; Hypnotics and Sedatives; Melatonin; Sleep Initiation and Maintenan

2017
Doxepin for insomnia: a systematic review of randomized placebo-controlled trials.
    Sleep medicine reviews, 2015, Volume: 19

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Doxepin; Drug Therapy,

2015
A Review of Suvorexant, Doxepin, Ramelteon, and Tasimelteon for the Treatment of Insomnia in Geriatric Patients.
    The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2017, Mar-01, Volume: 32, Issue:3

    Topics: Aged; Aged, 80 and over; Azepines; Benzofurans; Cyclopropanes; Doxepin; Humans; Hypnotics and Sedati

2017
Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines.
    CNS spectrums, 2008, Volume: 13, Issue:12

    Topics: Doxepin; Histamine Antagonists; Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedating; Hu

2008
Low-dose doxepin for the treatment of insomnia: emerging data.
    Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:10

    Topics: Antidepressive Agents, Tricyclic; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Doxep

2009
Low-dose doxepin: in the treatment of insomnia.
    CNS drugs, 2010, Volume: 24, Issue:8

    Topics: Adult; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Doxepin; Female; Humans; Male; Sl

2010
Low-dose doxepin (Silenor) for insomnia.
    The Medical letter on drugs and therapeutics, 2010, Oct-04, Volume: 52, Issue:1348

    Topics: Antidepressive Agents, Tricyclic; Chemistry, Pharmaceutical; Disorders of Excessive Somnolence; Doxe

2010
[The effects of antidepressants on sleep in depressed patients with particular reference to trazodone in comparison to agomelatine, amitriptyline, doxepin, mianserine and mirtazapine].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2011, Volume: 31, Issue:181

    Topics: Amitriptyline; Antidepressive Agents; Depression; Doxepin; Humans; Mianserin; Mirtazapine; Sleep; Sl

2011
Novel therapeutic usage of low-dose doxepin hydrochloride.
    Expert opinion on investigational drugs, 2007, Volume: 16, Issue:8

    Topics: Animals; Dose-Response Relationship, Drug; Doxepin; Drug Administration Schedule; Humans; Sleep Init

2007
Nocturnal melatonin secretion and its modification by treatment in patients with sleep disorders.
    Advances in experimental medicine and biology, 1999, Volume: 467

    Topics: Adult; Circadian Rhythm; Doxepin; Flunitrazepam; Humans; Hypnotics and Sedatives; Melatonin; Middle

1999

Trials

12 trials available for doxepin and Chronic Insomnia

ArticleYear
Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease -- a randomized study.
    Parkinsonism & related disorders, 2013, Volume: 19, Issue:7

    Topics: Actigraphy; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Cognitive Behavioral T

2013
Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study.
    The Journal of clinical psychiatry, 2008, Volume: 69, Issue:10

    Topics: Aged; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Doxepin; Drug-Relat

2008
Efficacy and safety of doxepin 6 mg in a model of transient insomnia.
    Sleep medicine, 2010, Volume: 11, Issue:9

    Topics: Adult; Double-Blind Method; Doxepin; Humans; Hypnotics and Sedatives; Polysomnography; Sleep; Sleep

2010
Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia.
    Sleep, 2010, Volume: 33, Issue:11

    Topics: Aged; Antidepressive Agents, Tricyclic; Chronic Disease; Dose-Response Relationship, Drug; Double-Bl

2010
Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia.
    Sleep, 2011, Oct-01, Volume: 34, Issue:10

    Topics: Adolescent; Adult; Chronic Disease; Double-Blind Method; Doxepin; Female; Humans; Hypnotics and Seda

2011
Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia.
    Sleep medicine, 2012, Volume: 13, Issue:2

    Topics: Aged; Aged, 80 and over; Chronic Disease; Doxepin; Female; Histamine H1 Antagonists; Humans; Male; M

2012
The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. A placebo-controlled, double-blind, randomized, cross-over study followed by an open treatment over 3 weeks.
    Psychopharmacology, 2003, Volume: 170, Issue:4

    Topics: Adult; Antidepressive Agents, Tricyclic; Cross-Over Studies; Double-Blind Method; Doxepin; Female; H

2003
Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia.
    Sleep, 2007, Volume: 30, Issue:11

    Topics: Adolescent; Adult; Antidepressive Agents, Tricyclic; Chronic Disease; Cross-Over Studies; Double-Bli

2007
Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia.
    Pharmacopsychiatry, 1996, Volume: 29, Issue:5

    Topics: Adult; Antidepressive Agents, Tricyclic; Area Under Curve; Arousal; Cross-Over Studies; Double-Blind

1996
Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study.
    The Journal of clinical psychiatry, 2001, Volume: 62, Issue:6

    Topics: Antidepressive Agents, Tricyclic; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Me

2001
A comparative study of antidepressants in the treatment of depressive states.
    The Journal of international medical research, 1976, Volume: 4, Issue:3

    Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Depression; Dibenzazepines; Dibenzocycloheptenes;

1976
A clinical study of insomnia.
    American family physician, 1975, Volume: 11, Issue:3

    Topics: Adult; Aged; Anxiety Disorders; Clinical Trials as Topic; Depression; Doxepin; Drug Therapy, Combina

1975

Other Studies

12 other studies available for doxepin and Chronic Insomnia

ArticleYear
Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.
    Bioorganic & medicinal chemistry letters, 2010, Oct-01, Volume: 20, Issue:19

    Topics: Animals; Cytochrome P-450 CYP2D6; Dimethindene; Electroencephalography; Histamine H1 Antagonists; Hu

2010
Chronic Doxepin Toxicity Masquerading as Epilepsy in a 10-Year-Old Boy.
    Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2023, Volume: 19, Issue:4

    Topics: Ataxia; Child; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Doxepin; Epilepsy; Humans; Male; S

2023
Doxepin in children and adolescents with symptoms of insomnia: a single-center experience.
    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2020, 05-15, Volume: 16, Issue:5

    Topics: Adolescent; Child; Doxepin; Humans; Melatonin; Retrospective Studies; Sleep; Sleep Initiation and Ma

2020
A novel neurological function of rice bran: a standardized rice bran supplement promotes non-rapid eye movement sleep in mice through histamine H
    Molecular nutrition & food research, 2017, Volume: 61, Issue:11

    Topics: Action Potentials; Animals; Dietary Fiber; Dietary Supplements; Doxepin; Electroencephalography; His

2017
[The interesting anti-H1 effects in maintenance insomnia: A reflection on the comparative advantages of doxylamine and doxepin].
    L'Encephale, 2020, Volume: 46, Issue:1

    Topics: Doxepin; Doxylamine; Histamine H1 Antagonists; Humans; Hypnotics and Sedatives; Patient Education as

2020
Insomnia: chasing the dream.
    Nature, 2013, May-23, Volume: 497, Issue:7450

    Topics: Animals; Arousal; Azabicyclo Compounds; Azepines; Benzodiazepines; Cognitive Behavioral Therapy; Dox

2013
Selective histamine H(1) antagonism: a novel approach to insomnia using low-dose doxepin.
    Drugs of today (Barcelona, Spain : 1998), 2009, Volume: 45, Issue:4

    Topics: Adult; Aged; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response

2009
FPIN's clinical inquiries: Antidepressants for the treatment of insomnia in patients with depression.
    American family physician, 2011, Nov-01, Volume: 84, Issue:9

    Topics: Amitriptyline; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depression; Dose-Response Re

2011
[Clonidine for the treatment of heroin withdrawal syndrome].
    Wiener klinische Wochenschrift, 1983, Aug-26, Volume: 95, Issue:16

    Topics: 2-Hydroxyphenethylamine; Clonidine; Dose-Response Relationship, Drug; Doxepin; Drug Administration S

1983
Melatonin in insomniac patients and effects of sleep medication.
    Advances in experimental medicine and biology, 1996, Volume: 398

    Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Double-Blind Method; Doxepin; Flunitra

1996
The jitteriness syndrome in panic disorder patients treated with antidepressants.
    The Journal of clinical psychiatry, 1988, Volume: 49, Issue:3

    Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Tricyclic; Anxiety Disorders; Depressive Diso

1988
Dystonic reactions to amitriptyline and doxepin.
    The American journal of psychiatry, 1988, Volume: 145, Issue:5

    Topics: Adult; Amitriptyline; Basal Ganglia Diseases; Depressive Disorder; Doxepin; Dystonia; Female; Humans

1988
chemdatabank.com